Amgen Collaboration Program

About Xeris Biopharma

Xeris Biopharma is a commercial-stage company that has successfully leveraged its proprietary formulation technology to bring novel, ready-to-use injectable products to market. Its core strategy involves developing stable liquid formulations of drugs that traditionally require complex reconstitution or refrigeration, thereby enhancing convenience, adherence, and safety. The company has built a commercial portfolio around its lead product, Gvoke® (glucagon), for severe hypoglycemia, and is advancing a pipeline of internal and partnered programs. As a publicly traded entity, Xeris faces the dual challenge of driving commercial execution for its approved products while funding the development of its pipeline in a competitive market.

Therapeutic Areas

Other Undisclosed Drugs